Source: Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
James D. Chalmers. Macrolide resistance in Pseudomonas aeruginosa: implications for practice. Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017

Member's Comments

No comment yet.

Related content which might interest you: Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 The impact of testosterone on Pseudomonas aeruginosa pathogenicity and antimicrobial susceptibility Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 The role of efflux pump systems and OprD porine in antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients with bronchiectasis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017 Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Source: Eur Respir J 2010; 35: 473-474 Year: 2010 PES (Pseudomonas , Enterobacteriaceae S. Aureus MR) a new clinical acronym to identify MDR pneumonias in the community Source: International Congress 2014 – Multidrug-resistant (MDR) pathogens that cause pneumonia Year: 2014 Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment Source: International Congress 2017 – Cystic fibrosis: clinical issues Year: 2017 Uncommon accumulation of multidrug resistance and virulence potential in carbapenemase ST-14 KPC-3 Klebsiella pneumoniae in Portugal: a high risk threat Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Mechanisms of acquisition of resistance in Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline. Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Can transmissible strains of Pseudomonas aeruginosa be successfully eradicated? Source: Eur Respir J 2011; 38: 1483-1486 Year: 2011 Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Source: Eur Respir J , 49 (4)  1600851; DOI: 10.1183/13993003.00851-2016 Year: 2017 Host response to transmissible Pseudomonas aeruginosa Source: Eur Respir J 2004; 23: 493-494 Year: 2004 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro Source: Eur Respir J 2003; 21: 401-406 Year: 2003 Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010